In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
The U.S. Supreme Court on Monday agreed to consider whether private parties should be allowed to bring claims that fund contracts violate the Investment Company Act ...
It's officially summertime, which means FBV's annual Summer Reading List is here. We curate the list each year by soliciting recommendations from our readers and friends ...
ASA Gold and Precious Metals Ltd. shareholders voted at a special meeting last week to enlarge the closed-end fund's board and elected a fifth independent director, one ...
Members of the Heartland Funds board and Heartland Advisors management team spent a recent evening together sharing a meal. Of course it's not unusual for independent ...